Vaccines against chlamydia sp
AssigneeStatens Serum Institut
InventorsFrank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
Life of this patent
Estimating the term…
Abstract
The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
Claims16
A nucleic acid encoding a polypeptide comprising 3 or more immuno-repeat units of surface exposed fragments of a Chlamydia major outer membrane protein (MOMP), each of said immune-repeat units comprising an amino acid sequence from a variable domain 4 (VD4) region selected from:
- VD4-SvD (SEQ ID NO:
- 15);
- VD4-SvE (SEQ ID NO:
- 16);
- VD4-SvF (SEQ ID NO:
- 17);
- VD4-Svla (SEQ ID NO:
- 18);
- VD4-SvG (SEQ ID NO:
- 19);
- VD4-SvJ (SEQ ID NO:
- 20);
- VD4extSvD (SEQ ID NO:
- 23);
- VD4extSvE (SEQ ID NO:
- 24);
- VD4extSvF (SEQ ID NO:
- 25);
- VD4extSvG (SEQ ID NO:
- 26);
- VD4extSvla (SEQ ID NO:
- 27);
- VD4extSvJ (SEQ ID NO:
- 28), wherein each of said at least 3 or more immuno-repeat units is from a different serovar, wherein optionally the cysteine residue in SEQ ID Nos:
- 17-18, 25-26 is substituted with serine to prevent formation of a disulfide bond.
Dependencies are inferred from the claim text.